The pharmaceutical company Merck on Tuesday sued the government over a federal law that empowers Medicare for the first time to negotiate prices directly with drugmakers.
Democrats pushed through the Medicare-negotiation program last summer as a provision of the Inflation Reduction Act, framing it as a way of lowering drug prices.
Only some drugs will be subject to negotiation with Medicare and only after they have been on the market without competition for years.
But Merck, which generated $14.5 billion in profit last year, claimed in a statement on Tuesday that the law would stifle its ability and that of its peers to make risky investments in new cures.
Other drug companies have suggested that they will choose to cut certain drug development programs because of the projected dent to their revenue.
Organizations:
Merck, Medicare
Locations:
Washington